FTSE MIB
33.835,36 -435,76 (-1,27%) Dow Jones
37.821,06 -639,86 (-1,66%) Nasdaq
15.405,92 -306,83 (-1,95%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,77 -0,04 (-0,05%) Bitcoin EUR
59.268,82 -2.613,41 (-4,22%)
Incyte Corporation (INCY)
| Chiusura precedente | 51,74 |
| Aperto | 51,65 |
| Denaro | 51,29 x 800 |
| Lettera | 51,48 x 800 |
| Min-Max giorno | 51,37 - 51,85 |
| Intervallo di 52 settimane | 50,27 - 75,74 |
| Volume | |
| Media Volume | 1.756.574 |
| Capitalizzazione | 11,538B |
| Beta (5 anni mensile) | 0,67 |
| Rapporto PE (ttm) | 19,39 |
| EPS (ttm) | 2,65 |
| Prossima data utili | 30 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 74,29 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
